Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276)

Overview

Jiangsu Hengrui Medicine Co., Ltd. is a prominent player in the global pharmaceutical industry, known for its extensive research, development, manufacturing, and marketing of drugs. Founded in 1970 and headquartered in Lianyungang, China, the company has established a significant presence worldwide. Its operations focus on innovating therapeutic solutions across various categories, including oncology, cardiovascular and metabolic disorders, autoimmune diseases, pain management, anti-infection, and other specialized areas. Jiangsu Hengrui Medicine is dedicated to improving patient care through its commitment to excellence in pharmaceutical development.

Products and Services

Jiangsu Hengrui Medicine Co., Ltd. has a diverse portfolio of products, particularly strong in developing treatments for oncology, cardiovascular and metabolism disorders, autoimmune diseases, pain management, and anti-infection. Some of their key products in development include:

• Camrelizumab, Pyrotinib, Fuzuloparib, Adebrelimab, Rezvilutamide, Famitinib, Dalpiciclib, SHR-1701, SHR-1501, SHR-A1811, SHR1459, Mecapegfilgrastim, Apatinib, Linperlisib, and SHR2554: A comprehensive array of oncology drugs aimed at treating various types of cancers through innovative mechanisms of action and targeted therapy.
• SHR4640, Retagliptin, SHR20004, SHR-1209, SHR3824, INS068, SHR7280, and SHR2285: These products are designed to address cardiovascular and metabolic diseases, offering new hope for patients with such health conditions.
• SHR0302, Hetrombopag, Vunakizumab, and SHR-1703: Focused on autoimmune diseases, these treatments aim to modulate the immune system to combat conditions such as arthritis and psoriasis effectively.
• SHR0410, Imrecoxib, Remimazolam, and SHR8554: Developed for pain management, these compounds offer innovative approaches to relieving chronic and acute pain, improving quality of life for patients suffering from various pain conditions.
• Oteseconazole and HRS9950: Targeting anti-infection, these drugs are designed to combat infectious diseases, ensuring better outcomes for patients grappling with infections.
• SHR8028, SHR8058, SHR-1707, and SHR-1222: This group includes treatments for a variety of other indications, demonstrating Jiangsu Hengrui Medicine's commitment to addressing a broad spectrum of healthcare needs through pharmaceutical innovation.